Cyclin-dependent protein kinases as therapeutic targets in cardiovascular disease

Bibliography

• ROSS R: Atherosclerosis: an inflammatory. N Engl. Med (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• STEINBERG D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8:1211–1217.
   PubMed Web of Science ®Google Scholar
• ••This review discusses very recent advancesin the understanding of the pathophysiology of atherosclerosis.
   Google Scholar
• SHIMIZU K, SUGIYAMA S, AIKAWA M et al.: Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat. Med. (2001) 7:738–741.
   PubMed Web of Science ®Google Scholar
• RELIGA P, BOJAKOWSKI K, M et al.: Smooth-muscle progenitor cells of bone marrow origin contribute to the development of neointimal thickenings in rat aortic allografts and injured rat carotid arteries. Transplantation (2002) 74:1310–1315.
   PubMed Web of Science ®Google Scholar
• SATA M, SAIURA A, KUNISATO A et al.: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. (2002) 8:403–409.
   PubMed Web of Science ®Google Scholar
• SARTORE S, CHIAVEGATO A, FAGGIN E et al.: Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. (2001) 89:1111–1121.
   PubMed Web of Science ®Google Scholar
• DZAU VJ, BRAUN-DULLAEUS RC, SEDDING DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. (2002) 8:1249–1256.
   PubMed Web of Science ®Google Scholar
• CORTES MJ, DIEZ-JUAN A, PEREZ P et al.: Increased early atherogenesis in young versus old hypercholesterolemic rabbits by a mechanism independent of arterial cell proliferation. FEBS Lett. (2002) 522:99–103.
   PubMed Web of Science ®Google Scholar
• DIEZ-JUAN A, ANDRES V: The growth suppressor p27KiP1 protects against diet-induced atherosclerosis. FASEB (2001) 15: 1989-1995.
   Google Scholar
• ROSS R: The pathogenesis of atherosclerosis:a perspective for the 1990s. Nature (1993) 362:801–809.
   PubMed Web of Science ®Google Scholar
• SPRARAGEN SC, BOND VP, DAHL LK: Role of hyperplasia in vascular lesions of cholesterol-fed rabbits studied with thymidine-3H autoradiography. Circ. Res. (1962) 11:329–336.
   PubMed Web of Science ®Google Scholar
• •Early demonstration of arterial cell proliferation during experimental atherogenesis.
   Google Scholar
• MCMILLAN GC, STARY HC: Preliminary experience with mitotic activity of cellular elements in the atherosclerotic plaques of cholesterol-fed rabbits studied by labeling with tritiated thymidine. Ann. NY Acad. Sci. (1968) 149:699–709.
   PubMed Web of Science ®Google Scholar
• ROSENFELD ME, ROSS R: Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis (1990) 10:680–687.
   PubMedGoogle Scholar
• BAUTERS C, ISNER JM: The biology of restenosis. Frog. Cardiovasc. Dis. (1997) 40:107–116.
   PubMed Web of Science ®Google Scholar
• ANDRES V: Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. Int. Molec. Med. (1998) 2:81–89.
   PubMed Web of Science ®Google Scholar
• LIBBY P, TANAKA H: The molecular basis of restenosis. Frog. Cardiovasc. Dis. (1997) 40:97–106.
   PubMed Web of Science ®Google Scholar
• BURRIG KF: The endothelium of advancedarteriosclerotic plaques in humans. Arteriosclec Thromb. (1991) 11:1678–1689.
   PubMedGoogle Scholar
• GORDON D, REIDY MA, BENDITT EP, SCHWARTZ SM: Cell proliferation in human coronary arteries. Proc. Nati Acad. ScL USA (1990) 87:4600–4604.
   PubMed Web of Science ®Google Scholar
• KATSUDA S, COLTRERA MD, ROSS R, GOWN AM: Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am. J. Pathol. (1993) 142:1787–1793.
   Google Scholar
• KEARNEY M, PIECZEK A, HALEY L et al.: Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation (1997) 95:1998–2002.
   PubMed Web of Science ®Google Scholar
• O'BRIEN ER, ALPERS CE, DK et al.: Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res. (1993) 73:223–231.
   Google Scholar
• OREKHOV AN, ANDREEVA ER, MIKHAILOVA IA, GORDON D: Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. Atherosclerosis (1998) 139:41–48.
   PubMed Web of Science ®Google Scholar
• REKHTER MD, GORDON D: Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am.j Pathol. (1995) 147:668–677.
   PubMed Web of Science ®Google Scholar
• TANNER FC, YANG Z-Y, DUCKERS E et al.: Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. (1998) 82:396–403.
   PubMed Web of Science ®Google Scholar
• VEINOT JP, MA X, JELLEY J,'BRIEN ER: Preliminary clinical experience with the pullback atherectomy catheter and the study of proliferation in coronary plaques. Can.' Cardiol. (1998) 14:1457–1463.
   PubMed Web of Science ®Google Scholar
• WEI GL, KRASINSKI K, KEARNEY M et al.: Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ. Res. (1997) 80:418–426.
   PubMed Web of Science ®Google Scholar
• ESSED CE, VAN DEN BRAND M, BECKER AE: Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. Br. Heart (1983) 49:393–396.
   Google Scholar
• NOBUYOSHI M, KIMURA T, OHISHI Het al.: Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients.' Am. Coll. Cardiol. (1991) 17:433–439.
   Google Scholar
• O'BRIEN ER, URIELI-SHOVAL S, GARVIN MR et al.: Replication in restenotic atherectomy tissue. Atherosclerosis (2000) 152:117–126.
   PubMedGoogle Scholar
• PICKERING JG, WEIR L, JEKANOWSKI J, KEARNEY MA, ISNER JM: Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. Clin. Invest. (1993) 91:1469–1480.
   Google Scholar
• ISNER JM: Vascular remodeling. Honey, I think I shrunk the artery. Circulation (1994) 89:2937–2941.
   PubMed Web of Science ®Google Scholar
• SAKAI M, KOBORI S, MIYAZAKI A, HORIUCHI S: Macrophage proliferation in atherosclerosis. Carr: Opin. Lipidol. (2000) 11:503–509.
   PubMed Web of Science ®Google Scholar
• DARTSCH PC, VOISARD R, G, HOFLING B, BETZ E: Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions. Arteriosclerosis (1990) 10:62–75.
   PubMedGoogle Scholar
• •This study demonstrates striking differences in the proliferative capacity of human VSMCs obtained from primary stenosing and restenosing lesions.
   Google Scholar
• MORGAN DO: Principles of CDK regulation. Nature (1995) 374:131–134.
   PubMed Web of Science ®Google Scholar
• STEVAUX 0, DYSON NJ: A revised picture of the E2F transcriptional network and RB function. Carr. Opin. Cell. Biol. (2002) 14:684–691.
   PubMed Web of Science ®Google Scholar
• PHILIPP-STAHELI J, PAYNE SR, CJ: p271(iP1: regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. (2001) 264:148–168.
   PubMed Web of Science ®Google Scholar
• BRAUN-DULLAEUS RC, MANN MJ, SEAY U et al.: Cell cycle protein expression in vascular smooth muscle cells M vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1152–1158.
   PubMed Web of Science ®Google Scholar
• ABE J, ZHOU W, TAGUCHI J et al: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. (1994) 198:16–24.
   PubMed Web of Science ®Google Scholar
• IHLING C, TECHNAU K, GROSS V et al.: Concordant upregulation of Type II-TGF-I3-receptor, the cyclin-dependent kinases inhibitor p27KiP1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis (1999) 144:7–14.
   PubMed Web of Science ®Google Scholar
• ANDRES V, CASTRO C: Antiproliferative strategies for the treatment of vascular proliferative disease. Curr: Vasc. Pharmacol (2003) 1:85–98.
   PubMedGoogle Scholar
• FISCHER PM: Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Carr. Opin. Drug Discov. Dev. (2001) 4:623–634.
   PubMedGoogle Scholar
• IVORRA C, SAMYN H, EDO MD et al: Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Curr. Pharm. Biotech. (2003) 4:21–37.
   PubMedGoogle Scholar
• BROOKS EE, GRAY NS, JOLY A et aL: CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. (1997) 272:29207–29211.
   PubMed Web of Science ®Google Scholar
• ••Initial description of a pharmacologicalCDK inhibitory agent that efficiently reduced experimental neointimal thickening after balloon angioplasty.
   Google Scholar
• RUEF J, MESHEL AS, HU Z et al.: Flavopiridol inhibits smooth muscle cell proliferation M vitro and neointimal formation in vivo after carotid injury in the rat. Circulation (1999) 100:659–665.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al: Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. Gin. Invest. (1994) 93:1458–1464.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, KANEDA Y, OGIHARA T, DZAU VJ: Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene (1994) 149:13–19.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al: Single intraluminal delivery of antisense cdc2kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA (1993) 90:8474–8478.
   PubMed Web of Science ®Google Scholar
• ••First study to demonstrate reducedexperimental neointimal thickening by targeting CDK activity with an antisense ODN.
   Google Scholar
• ROBINSON KA, CHRONOS NA, SCHIEFFER E et al: Endoluminal local delivery of PCNA/cdc2antisense oligonucleotides by porous balloon catheter does not affect neointima formation or vessel size in the pig coronary artery model of postangioplasty restenosis. Gather Cardiovasc. Diagn. (1997) 41:348–353.
   PubMedGoogle Scholar
• ZHU NL, WU L, LIU PX et al.: of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation (1997) 96:628–635.
   PubMed Web of Science ®Google Scholar
• SUZUKI J-I, ISOBE M, MORISHITA R et al.: Prevention of graft coronary arteriosclerosis by antisense edk2kinase oligonucleotide. Nat. Med. (1997) 3:900–903.
   PubMed Web of Science ®Google Scholar
• MANN M, GIBBONS GH, KERNOFF RS et al: Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. USA (1995) 92:4502–4506.
   PubMed Web of Science ®Google Scholar
• HU WY, FUKUDA N, NAKAYAMA M, KISHIOKA H, KANMATSUSE K: Inhibition of vascular smooth muscle cell proliferation by DNA-RNA chimeric hammerhead ribozyme targeting to rat platelet-derived growth factor A-chain mRNA. Hypertens. (2001) 19:203–212.
   Web of Science ®Google Scholar
• HU WY, FUKUDA N, KISHIOKA H et al: Hammerhead ribozyme targeting human platelet-derived growth factor A-chain mRNA inhibited the proliferation of human vascular smooth muscle cells. Atherosclerosis (2001) 158:321–329.
   PubMed Web of Science ®Google Scholar
• FRIMERMAN A, WELCH PJ, JINX et al.: Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation (1999) 99:697 703.
   Google Scholar
• ••Initial description of an antiproliferativestrategy based on the use of a chimeric DNA-RNA hammerhead ribozyme that efficiently reduced experimental coronary restenosis.
   Google Scholar
• YAMAMOTO K, MORISHITA R, TOMITA N et al.: Ribozyme oligonucleotides against transforming growth factor-I3 inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation (2000) 102:1308–1314.
   PubMed Web of Science ®Google Scholar
• CHEN D, KRASINSKI K, CHEN D et al.: of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27KiP1, an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. (1997) 99:2334–2341.
   PubMed Web of Science ®Google Scholar
• •First study supporting the notion that upregulation of endogenous CKIs at late time points after experimental angioplasty may contribute to limiting neointimal hyperplasia.
   Google Scholar
• BRAUN-DULLAEUS RC, MANN MJ, ZIEGLER A, VON DER LEYEN HE, DZAU VJ: A novel role for the cyclin-dependent kinase inhibitor p271(10 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. j. Clin. Invest. (1999) 104:815–823.
   PubMed Web of Science ®Google Scholar
• •Initial description of the role of p27KiP1 in the control of VSMC hypertropic growth.
   Google Scholar
• SERVANT MJ, COULOMBE P, TURGEON B, MELOCHE S: Differential regulation of p271('P1 expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J. Cell Biol. (2000) 148:543–556.
   PubMed Web of Science ®Google Scholar
• CHEN D, WALSH K, WANG J: Regulationof cdk2 activity in endothelial cells that are inhibited from growth by cell contact. Arteriosekr. DIF017111. V3SC. Biol. (2000) 20:629–635.
   PubMed Web of Science ®Google Scholar
• GOUKASSIAN D, DIEZ-JUAN A, ASAHARA T et al.: Overexpression of p27KiP1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB.I. (2001) 15:1877–1885.
   PubMed Web of Science ®Google Scholar
• KOYAMA H, RAINES EW, KE, ROBERTS JM, ROSS R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell (1996) 87:1069–1078.
   PubMed Web of Science ®Google Scholar
• ••This study supports the notion that p27K1P1and p21C1P1 play a critical role in integrin-dependent control of VSMC proliferation in vitro.
   Google Scholar
• KOH KN, KANG MJ, FRITH-TERHUNE A et al: Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KiP1, in rat hearts during development. J. MM. Cell Cardiol (1998) 30:463–474.
   PubMed Web of Science ®Google Scholar
• POOLMAN RA, LI JM, DURAND B, BROOKS G: Altered expression of cell cycle proteins and prolonged duration of cardiac myocyte hyperplasia in p27KiP1 knockout mice. Circ. Res. (1999) 85:117–127.
   PubMed Web of Science ®Google Scholar
• ROQUE M, REIS ED, CORDON-CARDO C et al.: Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab. Invest. (2001) 81:895–903.
   PubMed Web of Science ®Google Scholar
• CHAMLEY-CAMPBELL JH, GR, ROSS R: Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J. Cell Biol. (1981) 89:379–383.
   PubMed Web of Science ®Google Scholar
• MAJACK RA, GRIESHABER NA, COOK CL et al.: Smooth muscle cells isolated from the neointima after vascular injury exhibit altered responses to platelet-derived growth factor and other stimuli. J. Cell Physiol (1996) 167:106–112.
   PubMed Web of Science ®Google Scholar
• BOCHATON-PIALLAT ML, ROPRAZ P, GABBIANI F, GABBIANI G: Phenotypic heterogeneity of rat arterial smooth muscle cell clones. Implications for the development of experimental intimal thickening. Arterioscler. Thromb. Vasc. Biol. (1996) 16:815–820.
   PubMed Web of Science ®Google Scholar
• TOPOUZIS S, MAJESKY MW: Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-P. Dev. Biol. (1996) 178:430-445..LI S, FAN YS, CHOW LH et al.: Innate of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ. Res. (2001) 89:517–525.
   Google Scholar
• YANG Z, OEMAR BS, CARREL T et al: Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation (1998) 97:181–187.
   PubMed Web of Science ®Google Scholar
• OLSON NE, KOZLOWSKI J, REIDY MA: Proliferation of intimal smooth muscle cells. Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors. Chem. (2000) 275:11270–11277.
   Google Scholar
• CASTRO C, DIEZ-JUAN A, CORTES MJ, ANDRES V: Distinct regulation of mitogen-activated protein kinases and p27KiP1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J. Biol. Chem. (2003) 278:4482–4490.
   Google Scholar
• IHLING C, MENZEL G, WELLENS E et al.: Topographical association between the cyclin-dependent kinases inhibitor p21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arteriosclec Thromb. Vasc. Biol. (1997) 17:2218–2224.
   PubMed Web of Science ®Google Scholar
• CHANG MW, BARR E, LU MM, BARTON K, LEIDEN JM: Adenovirus-mediated over-expression of the cyclin/ cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. (1995) 96:2260–2268.
   PubMed Web of Science ®Google Scholar
• ••First study reporting the efficacy of CKIoverexpression in reducing neointimal hyperplasia after experimental balloon angioplasty.
   Google Scholar
• UENO H, MASUDA S, SNISHIO S et al.: Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann. NY Acad. Sci. (1997) 811:401–411.
   PubMed Web of Science ®Google Scholar
• YANG Z-Y, SIMARI RD, PERKINS ND et al.: Role of p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Si". USA (1996) 93:7905–7910.
   Google Scholar
• CONDORELLI G, AYCOCK JK, FRATI G, NAPOLI C: Mutated p21/WAF/ CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB (2001) 15:2162–2170.
   PubMed Web of Science ®Google Scholar
• TANNER FC, BOEHM M, AKYOREK LM et al.: Differential effects of the cyclin-dependent kinase inhibitors p27K'P1, p21QP1, and p164 on vascular smooth muscle cell proliferation. Circulation (2000) 101: 2022-2025.
   Google Scholar
• BAI H, MORISHITA R, KIDA I et al.: Inhibition of intimal hyperplasia after vein grafting by M vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. (1998) 5:761-769..CALIFF RM, FORTIN DF, FRID DJ et al: after coronary angioplasty: an overview. Am. Coll Cardiol (1991) 17:2B–13B.
   Google Scholar
• CHAN AW, CHEW DP, LINCOFF AM: Update on pharmacology for restenosis. Curl: Interv. Cardiol Rep. (2001) 3:149–155.
   PubMedGoogle Scholar
• FRANKLIN SM, FAXON DP: prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery AK (1993) 4:232–242.
   PubMed Web of Science ®Google Scholar
• POPMA JJ, CALIFF RIVI, TOPOL EJ: Clinical trials of restenosis after coronary angioplasty. Circulation (1991) 84:1426–1436.
   PubMed Web of Science ®Google Scholar